These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 15023581)

  • 41. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
    Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
    Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A
    Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia.
    Simonsen AH; McGuire J; Podust VN; Hagnelius NO; Nilsson TK; Kapaki E; Vassilopoulos D; Waldemar G
    Dement Geriatr Cogn Disord; 2007; 24(6):434-40. PubMed ID: 17971664
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evidence that Abeta42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype.
    De Jonghe C; Cras P; Vanderstichele H; Cruts M; Vanderhoeven I; Smouts I; Vanmechelen E; Martin JJ; Hendriks L; Van Broeckhoven C
    Neurobiol Dis; 1999 Aug; 6(4):280-7. PubMed ID: 10448055
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increasing the predictive accuracy of amyloid-β blood-borne biomarkers in Alzheimer's disease.
    Watt AD; Perez KA; Faux NG; Pike KE; Rowe CC; Bourgeat P; Salvado O; Masters CL; Villemagne VL; Barnham KJ
    J Alzheimers Dis; 2011; 24(1):47-59. PubMed ID: 21157020
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
    Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasma beta carotene in Alzheimer's disease. Association with cerebrospinal fluid beta-amyloid 1-40, (Abeta40), beta-amyloid 1-42 (Abeta42) and total Tau.
    Stuerenburg HJ; Ganzer S; Müller-Thomsen T
    Neuro Endocrinol Lett; 2005 Dec; 26(6):696-8. PubMed ID: 16380679
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEε4 genotype.
    Popp J; Lewczuk P; Frommann I; Kölsch H; Kornhuber J; Maier W; Jessen F
    J Alzheimers Dis; 2010; 22(2):459-68. PubMed ID: 21084733
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients.
    Hansson SF; Andréasson U; Wall M; Skoog I; Andreasen N; Wallin A; Zetterberg H; Blennow K
    J Alzheimers Dis; 2009; 16(2):389-97. PubMed ID: 19221428
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Blood-based neurochemical diagnosis of vascular dementia: a pilot study.
    Bibl M; Esselmann H; Mollenhauer B; Weniger G; Welge V; Liess M; Lewczuk P; Otto M; Schulz JB; Trenkwalder C; Kornhuber J; Wiltfang J
    J Neurochem; 2007 Oct; 103(2):467-74. PubMed ID: 17662050
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration.
    Noguchi M; Yoshita M; Matsumoto Y; Ono K; Iwasa K; Yamada M
    J Neurol Sci; 2005 Oct; 237(1-2):61-5. PubMed ID: 15992827
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease.
    Ewers M; Zhong Z; Bürger K; Wallin A; Blennow K; Teipel SJ; Shen Y; Hampel H
    Brain; 2008 May; 131(Pt 5):1252-8. PubMed ID: 18334538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plasma biomarkers of Alzheimer's disease.
    Kawarabayashi T; Shoji M
    Curr Opin Psychiatry; 2008 May; 21(3):260-7. PubMed ID: 18382225
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
    Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease.
    Zetterberg H; Andreasen N; Blennow K
    Neurosci Lett; 2004 Sep; 367(2):194-6. PubMed ID: 15331151
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Electrophoretic separation of amyloid beta peptides in plasma.
    Lewczuk P; Esselmann H; Bibl M; Paul S; Svitek J; Miertschischk J; Meyrer R; Smirnov A; Maler JM; Klein C; Otto M; Bleich S; Sperling W; Kornhuber J; Rüther E; Wiltfang J
    Electrophoresis; 2004 Oct; 25(20):3336-43. PubMed ID: 15490456
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI.
    Nordlund A; Rolstad S; Klang O; Lind K; Pedersen M; Blennow K; Edman A; Hansen S; Wallin A
    J Int Neuropsychol Soc; 2008 Jul; 14(4):582-90. PubMed ID: 18577287
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels.
    Abdullah L; Paris D; Luis C; Quadros A; Parrish J; Valdes L; Keegan AP; Mathura V; Crawford F; Mullan M
    Neurosci Lett; 2007 Nov; 428(2-3):53-8. PubMed ID: 17964720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Study on the association between SOAT1 polymorphisms, Alzheimer's disease risk and the level of CSF biomarkers.
    Lamsa R; Helisalmi S; Herukka SK; Tapiola T; Pirttila T; Vepsalainen S; Hiltunen M; Soininen H
    Dement Geriatr Cogn Disord; 2007; 24(2):146-50. PubMed ID: 17622762
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.
    Liu K; Solano I; Mann D; Lemere C; Mercken M; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2006 Aug; 112(2):163-74. PubMed ID: 16865398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.